Access for All was launched in 2019 and has already driven major change. We are fortunate to have some of the most powerful young voices in the country advocating for […]
Summer is here and as Canadians are getting vaccinated against COVID-19, we have decided to take a break from our live Let’s Talk T1D events on Microsoft Teams, and package them in […]
Type 1 diabetes is an autoimmune disease resulting in a lifelong dependency on insulin treatment and a risk of serious long-term complications. The cause of the disease is unclear, although […]
We’re heading into the summer, and after a long Canadian winter, many of us are more than ready to head outdoors. But the summer season also means some different planning […]
Joseph Segal is a 96-year-old World War II vet and renowned business tycoon. As the founder of Fields stores and President of Kingswood Capital Corporation, Joseph Segal has built an […]
Adolescence can be a challenging time to manage type 1 diabetes (T1D). Life (and hormones!) change in all sorts of ways, and many teenagers experience higher than recommended blood glucose […]
Canada holds a special place in the story of insulin because scientists Banting and Best made the discovery at the University of Toronto, in 1921. Before the discovery, the lives […]
This June, Canadians from coast to coast will be coming together to unite, raise funds and help accelerate the pace of type 1 diabetes (T1D) research as part of the […]
JDRF Canada is thrilled that federal budget 2021 includes new funding for type 1 diabetes research, as well as support for a national diabetes framework and improvements to the Disability […]
May 4th, 2021 “Insulin is not a cure for diabetes; it is a treatment.” – Dr. Frederick Banting 2021 marks the 100th anniversary of the discovery of insulin by researchers […]
Update: May 3, 2021: Ontario: As of May 10, 2021 anyone over 16 with type 1 diabetes can book a vaccine throughout the province. Alberta: Children aged 12 -15 with type 1 […]
May 4th, 2021 On April 15, 2021 the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for vTv Therapeutics’ TTP399 as an adjunct therapy to insulin for type 1 diabetes […]
